Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 12/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223912 | 1.00 | JAK2 (0.45) | JAK2JAK1SIGMAR1GPR119TACR1 | |
| SCHEMBL5223918 | 1.00 | JAK2 (0.45) | JAK2JAK1SIGMAR1GPR119TACR1 | |
| SCHEMBL26399598 | 0.89 | SIGMAR1 (0.48) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12435283 | 0.89 | SIGMAR1 (0.48) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22721969 | 0.87 | SIGMAR1 (0.43) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5221681 | 0.83 | GPR119 (0.47) | JAK2JAK1GPR119TACR1USP30 | |
| SCHEMBL5227765 | 0.83 | GPR119 (0.47) | JAK2JAK1GPR119TACR1USP30 | |
| SCHEMBL5226606 | 0.83 | GPR119 (0.47) | JAK2JAK1GPR119TACR1USP30 | |
| SCHEMBL30368581 | 0.82 | SIGMAR1 (0.52) | JAK2JAK1SIGMAR1GPR119USP30 | |
| SCHEMBL14372572 | 0.79 | TACR1 (0.43) | TACR1USP30CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1789389-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006030984-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | AVPR1B, PRLHR, HRH4 | JAK2 135/4885JAK1 1097/4885SIGMAR1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.